Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Prabodh Kumar Das"'
Publikováno v:
International Archives of Health Sciences, Vol 6, Iss 2, Pp 73-77 (2019)
Aim: This study aims to review the current literature and to focus on etiopathogenesis, clinical profile, diagnosis, and treatment of extranodal nasofacial natural killer (NK)/T-cell lymphoma. Materials and Methods: It is based upon the available lit
Externí odkaz:
https://doaj.org/article/f803d80e02a94466a4fefa2d32789804
Publikováno v:
Pediatric hematology and oncology. 39(6)
Children with underlying cancer are often immunocompromised. Data on severity of coronavirus disease 2019 (COVID-19) in children with cancer and its outcomes is emerging. Treatment protocols of specific cancers are decided based on the infrastructure
Autor:
Gaurav Chhabra, Somanath Padhi, Shruti Mishra, Rajesh Kumar Bhola, Prabodh Kumar Das, Manoj Kumar Panigrahi, Sandeep Abhijit Pattnaik
Publikováno v:
Blood research
Autor:
Sarita Pradhan, Kaushambi Chakraborty, Prabodh Kumar Das, SK Mishra, Rajesh Kumar Bhola, Soumya Surat Panda, Debahuti Mohapatra, Priyanka Samal, Pritish Chandra Patra
Publikováno v:
Journal of Hematopathology. 13:13-24
The diagnosis of chronic lymphoproliferative disorder (CLPD) or non-Hodgkin Lymphoma (NHL) is based on the detection of the abnormal clonal lymphoid cells. The flow cytometry (FCM) immunophenotyping not only plays an essential role in the screening o
Autor:
Somanath Padhi, Sandeep Abhijit Pattnaik, Amit Kumar Adhya, Gayatri Behera, Susama Patra, Prabodh Kumar Das
Publikováno v:
Indian Journal of Nephrology
Indian Journal of Nephrology, Vol 30, Iss 2, Pp 113-116 (2020)
Indian Journal of Nephrology, Vol 30, Iss 2, Pp 113-116 (2020)
Acquired pure red cell aplasia (PRCA) following use of recombinant erythropoietin (rEPO) is distinctly rare and sporadically reported in the literature. We discuss a case of PRCA following the usage of rEPO (darbepoetin-α) during the management of a
Publikováno v:
Global Journal of Transfusion Medicine, Vol 4, Iss 2, Pp 237-239 (2019)
Transfusion support remains the mainstay of supportive treatment for thalassemia patients in spite of recent advances such as stem cell transplantation and gene therapy. Thalassemia intermedia (TI) patients generally do not require regular transfusio
Externí odkaz:
https://doaj.org/article/fc5e1c15d605416598edb0e436c8c686